GENEVA, July 1 -- STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. filed a patent application (CN2025/140956) for “TACI FUSION PROTEIN AND USE THEREOF”. With publication no. WO/2026/124436, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: C07K 16/46
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....